Results 11 to 20 of about 9,708,599 (370)

Alzheimer disease [PDF]

open access: yesNature Reviews Disease Primers, 2021
Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants.
David S. Knopman   +7 more
openaire   +3 more sources

2023 Alzheimer's disease facts and figures

open access: yesAlzheimer's & Dementia, 2023
This article describes the public health impact of Alzheimer's disease, including prevalence and incidence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society.

semanticscholar   +1 more source

Lecanemab in Early Alzheimer's Disease.

open access: yesNew England Journal of Medicine, 2022
BACKGROUND The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease.
C. V. van Dyck   +18 more
semanticscholar   +1 more source

New insights into the genetic etiology of Alzheimer’s disease and related dementias

open access: yesNature Genetics, 2022
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes.
C. Bellenguez   +402 more
semanticscholar   +1 more source

Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease

open access: yesAlzheimer’s Research & Therapy, 2021
Background Comprehensive testing of cognitive functioning is standard practice in studies of Alzheimer disease (AD). Short-form tests like the Montreal Cognitive Assessment (MoCA) use a “sampling” of measures, administering key items in a shortened ...
Jason Hassenstab   +7 more
doaj   +1 more source

The Importance of Advancing Research on Aging and Driving

open access: yesGeriatrics, 2021
Between 2009 and 2018, the number of older adults (i [...]
Samantha A. Murphy   +2 more
doaj   +1 more source

Angiotensin II Receptor Blockers Reduce Tau/Aß42 Ratio: A Cerebrospinal Fluid Biomarkers’ Case-Control Study

open access: yesPharmaceutics, 2023
(1) Background: The role of antihypertensives in Alzheimer’s Disease (AD) prevention is controversial. This case-control study aims to assess whether antihypertensive medication has a protective role by studying its association with amyloid and tau ...
Gemma García-Lluch   +5 more
doaj   +1 more source

2021 Alzheimer's disease facts and figures

open access: yesAlzheimer's & Dementia, 2021
This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report discusses the challenges
Anonymous
semanticscholar   +1 more source

TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease

open access: yesActa Neuropathologica Communications, 2018
TDP-43 pathology was investigated in the anterior temporal pole cortex (ATPC) and orbital frontal cortex (OFC), regions often degenerated in frontotemporal lobar degenerations (FTLD), in aging and Alzheimer’s disease (AD).
Sukriti Nag   +5 more
doaj   +1 more source

A Novel NIR-FRET Biosensor for Reporting PS/γ-Secretase Activity in Live Cells

open access: yesSensors, 2020
Presenilin (PS)/γ-secretase plays a pivotal role in essential cellular events via proteolytic processing of transmembrane proteins that include APP and Notch receptors. However, how PS/γ-secretase activity is spatiotemporally regulated by other molecular
Mei CQ Houser   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy